The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
Despite fears that surging GLP-1 weight loss drugs would slash snack sales, new USDA data shows units holding steady at over 10 billion annually through 2024. Prescriptions rose from 0.5% to 2% of adults, yet food consumption patterns surprise economists. Discover the resilience, consumer shifts, and future outlook.
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
A man who shed six stone on Mounjaro shares his dramatic transformation from 123kg, but warns of 'horrible' side effects like chronic vomiting and dehydration no one mentioned. Despite the challenges, he reduced hypertension meds and gained food control. Discover his full story and management strategies.
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
A Rhode Island mother battled alcoholism for years, losing custody of her son—until GLP-1 drugs like Wegovy changed everything. In a pilot program at Open Doors transitional home, Gina Roberts stopped her cravings, got sober for two years, and rebuilt her life. Addiction specialists share why these weight-loss meds show promise for addiction recovery.
